BVF Partners XOMAP Position
ActiveBVF Partners held their position in XOMA Royalty Corp (XOMAP) in Q4 2025, holding $68.9M worth of shares across 2,590,303 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
About XOMA Royalty Corp
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Full company profile →BVF Partners XOMAP Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 2,590,303 | — | $68.9M |
| Q3 2025 | Held | 2,590,303 | — | $99.8M |
| Q2 2025 | Decreased | 2,590,303 | -392,723 | $65.3M |
| Q1 2025 | Decreased | 2,983,026 | -650,717 | $59.5M |
| Q4 2024 | Held | 3,633,743 | — | $95.5M |
| Q3 2024 | Held | 3,633,743 | — | $96.2M |
| Q2 2024 | Held | 3,633,743 | — | $86.1M |
| Q1 2024 | Held | 3,633,743 | — | $87.4M |
| Q4 2023 | Held | 3,633,743 | — | $67.2M |
| Q3 2023 | Held | 3,633,743 | — | $51.2M |
| Q2 2023 | Held | 3,633,743 | — | $68.6M |
| Q1 2023 | New | 3,633,743 | +3,633,743 | $76.7M |
Frequently Asked Questions
Does BVF Partners own XOMAP?
Yes. As of Q4 2025, BVF Partners holds 2,590,303 shares of XOMA Royalty Corp (XOMAP) valued at $68.9M. This data comes from their SEC 13F filing.
How many hedge funds own XOMAP?
1 specialist biotech hedge fund currently holds XOMAP. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did BVF Partners first buy XOMAP?
BVF Partners's position in XOMAP was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is BVF Partners's XOMAP position increasing or decreasing?
BVF Partners held their XOMAP position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
XOMAPCompany Page →
All fund holders, insider trades, catalysts, and cash runway
BVF PartnersPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →